-
GeoVax Highlights the Role of MVA-Based Vaccines in Advancing Public Health Preparedness
Recent Studies Support Diversified Vaccine Strategies, Aligning with GeoVax’s MVA-Based GEO-CM04S1 for Enhanced Protection, Particularly for Immunocompromised Populations ATLANTA, GA, February 24, 2025 – GeoVax…
-
Mpox Clade 1 in the U.S. Highlights the Need for Vaccine Supply Diversification
GeoVax Advances GEO-MVA to Strengthen U.S. and Global Readiness ATLANTA, GA, February 19, 2025 – The confirmation of a fourth case of Clade 1…
-
GeoVax Pledges Continued Support for Vaccine Innovation, Transparency, and Public Health
GeoVax’s Vaccine Development Programs Align with Anticipated HHS Focus on Vaccine Safety, Diversification and Domestic Biosecurity ATLANTA, GA, February 18, 2025 – GeoVax Labs,…
-
GeoVax to Present at the Emerging Growth Conference on February 19, 2025
Company to Provide an Update on its Mpox Vaccine Program ATLANTA, GA, February 17, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology…
-
GeoVax Congratulates Dr. Valerie Montgomery Rice on Receiving the 2025 Healthcare Champions Lifetime Achievement Award
Recognizing a Visionary Leader in Advancing Healthcare Access for Minority and Vulnerable Populations Worldwide ATLANTA, GA, February 11, 2025 – GeoVax Labs, Inc.…
-
GeoVax Anticipates Significant 2025 Progress with Catalyst-Rich Milestones Across Key Programs
Strategic Progress Across COVID-19, Mpox, Oncology Therapies and AI Integration Positions GeoVax for Strong Momentum Atlanta, GA – February 5, 2025 – GeoVax…
-
GeoVax to Showcase Advancements in Vaccines & Immunotherapies at the 2025 BIO CEO & Investor Conference
ATLANTA, GA, February 4, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced…
-
GeoVax Announces Strategic Integration of AI in Support of President Trump’s Stargate Initiative
Harnessing AI to Revolutionize Vaccine and Therapy Development ATLANTA, GA, February 3, 2025 — GeoVax Labs, Inc. (Nasdaq: GOVX), a leader in vaccine and…
-
GeoVax Advanced MVA Manufacturing Process: Aimed to Enhance Vaccine Supply Worldwide
Process Expected to Increase Production Yield, Flexibility at Lower Cost Atlanta, GA – January 27, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage…
-
GeoVax Announces Major Gedeptin® Milestone with Plans of Phase 2 Trial
Represents a Key Step Toward Validating Gedeptin Potential in Solid Tumor Therapy Atlanta, GA, January 15, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a…
-
GeoVax Achieves Significant Progress in Next-Generation COVID-19 Vaccine Development Throughout 2024
Advancements Position GEO-CM04S1 as a Leading Vaccine Candidate Addressing Unmet Medical Needs, Especially Among Immunocompromised Patients ATLANTA, GA, January 13, 2025 – GeoVax…
-
GeoVax to Review 2024 Progress at the Emerging Growth Conference on January 16, 2025
Company to provide updates on progress toward the BARDA-funded Phase 2b trial of GEO-CM04S1, its next-generation COVID-19 vaccine as well as for Gedeptin® (solid…